How many clinical trials have been conducted on Sincalide?

Eight clinical trials are currently registered for Sincalide in the ClinicalTrials.gov database. These trials focus on diagnostic imaging protocols, dose optimization, and population-specific applications. Unlike investigational compounds, Sincalide trials aim to refine clinical use rather than establish foundational safety or efficacy.

What evidence grade does Sincalide have?

Sincalide holds a Grade A evidence rating—the highest classification. This reflects consistent results across multiple randomized controlled trials, decades of clinical use, regulatory approval in major markets, and strong mechanistic understanding. Grade A evidence provides the strongest foundation for clinical decision-making.

Why isn't Sincalide approved in Europe?

The EMA has not authorized Sincalide, likely due to market size and the availability of alternative diagnostic methods in EU countries. This regulatory difference reflects economic and clinical practice factors rather than safety or efficacy concerns. Sincalide remains FDA-approved in the US and Health Canada-approved in Canada.

What are the main gaps in Sincalide research?

Key gaps include: the relationship between abnormal imaging findings and symptom resolution after intervention, whether Sincalide is overly sensitive in certain populations, optimal dosing in pediatric patients, and limited head-to-head comparisons with newer diagnostic modalities like advanced MRI or elastography.

Is Sincalide used only for diagnosis, or does it treat conditions?

Sincalide is approved and used exclusively as a diagnostic agent—it's injected during imaging studies to assess gallbladder function. It is not used as a therapeutic treatment for biliary conditions. Its role is to help clinicians identify functional abnormalities that may require further management.

Sincalide Research Evidence: Clinical Trials & Studies

Sincalide is an FDA-approved diagnostic peptide that mimics cholecystokinin (CCK), a natural hormone that triggers gallbladder contraction. It's used clinically to assess gallbladder function and biliary dyskinesia. Unlike most peptides discussed in research contexts, Sincalide has robust clinical validation—8 registered clinical trials and decades of use in diagnostic imaging. The research evidence supporting Sincalide is Grade A, meaning it's backed by randomized controlled trials and consistent observational data. This deep-dive covers the clinical trial landscape, key findings, regulatory approval pathways, and what remains unknown.

The Clinical Trial Landscape

Sincalide sits at an unusual intersection: it's a peptide therapeutic that's been approved for diagnostic use rather than disease treatment. The FDA approved Sincalide in 1983 for hepatobiliary imaging. Health Canada followed with approval, cementing its status in North America.

Currently, 8 registered clinical trials are associated with Sincalide in the ClinicalTrials.gov database. These trials span diagnostic imaging protocols, gallbladder function assessment, and optimization of imaging techniques. Unlike investigational compounds, Sincalide trials focus on refining clinical application rather than establishing safety or efficacy for a novel indication.

Key Study Designs

The Sincalide research portfolio includes:

Diagnostic imaging trials: Comparing Sincalide-augmented scintigraphy (imaging) to standard imaging in biliary dyskinesia diagnosis
Dose-response studies: Establishing optimal Sincalide dosing for reliable gallbladder contraction
Protocol optimization: Testing timing, imaging sequences, and patient preparation
Population-specific studies: Evaluating performance in pediatric and geriatric cohorts

These designs reflect a mature compound—research questions center on how best to use it, not whether it works.

What the Research Shows: Grade A Evidence

Sincalide has earned an A-grade evidence rating, the highest classification. Here's what the clinical data demonstrates:

Efficacy in Gallbladder Imaging

Studies confirm that intravenous Sincalide reliably triggers gallbladder contraction within 5–15 minutes of administration. This response is consistent, dose-dependent, and reproducible across patient populations. Serial imaging after Sincalide injection reveals gallbladder ejection fractions—a key diagnostic metric for distinguishing functional gallbladder disease from other causes of biliary pain.

Diagnostic Accuracy

Sincalide-stimulated hepatobiliary scintigraphy (often called CCK-HIDA scanning) has become the gold-standard test for biliary dyskinesia. Research demonstrates sensitivity and specificity rates exceeding 85–90% for detecting abnormal gallbladder function, substantially outperforming unstimulated imaging alone.

Safety Profile

Decades of clinical use have established Sincalide as a well-tolerated diagnostic agent. Adverse events are mild and transient, typically limited to temporary abdominal cramping or nausea—effects directly related to its intended mechanism (gallbladder contraction). Serious adverse events are extraordinarily rare in the diagnostic context.

Regulatory Approval Pathways

United States (FDA): Sincalide is FDA-approved as Kinevac®, the branded diagnostic agent. Approval was granted under a streamlined pathway due to its well-established mechanism and low toxicity profile.

Canada: Health Canada authorized Sincalide for clinical imaging use, aligning with North American standards.

European Union: Notably, the EMA has not authorized a Sincalide product, likely due to market size and the availability of alternative diagnostic methods in EU countries. This regulatory asymmetry reflects economic and clinical practice differences rather than safety or efficacy concerns.

Key Research Milestones

1980s–1990s: Establishing the Foundation

Early trials validated that synthetic Sincalide mimics natural CCK and safely stimulates biliary contraction. Researchers standardized imaging protocols and established diagnostic thresholds for gallbladder ejection fraction (typically >35% is considered normal).

2000s–2010s: Clinical Optimization

As diagnostic imaging technology evolved, Sincalide research focused on protocol refinement. Studies explored:

Optimal timing of Sincalide injection relative to imaging
Effects of patient fasting state
Reproducibility across imaging modalities (nuclear medicine, ultrasound-assisted)

Recent Decade: Niche Population Studies

Recent trials have examined Sincalide performance in:

Pediatric patients: Children with suspected biliary dyskinesia, where standard diagnostic criteria may differ
Post-bariatric surgery cohorts: Patients after gastric bypass or other GI surgery, where anatomical changes complicate imaging
Chronic pain populations: Refining patient selection for Sincalide-stimulated imaging

Evidence Gaps and Ongoing Questions

Despite strong Grade A evidence for diagnostic utility, research gaps remain:

1. Predictive Value for Symptom Resolution

While Sincalide-stimulated imaging identifies abnormal gallbladder function, the relationship between imaging findings and symptom improvement after intervention (e.g., cholecystectomy) remains incompletely characterized. Not all patients with abnormal ejection fractions benefit from surgery, suggesting additional biologic or psychosocial factors drive outcomes.

2. Mechanism Specificity

Sincalide works as a CCK-receptor agonist, but whether the diagnostic response reflects "true" pathology versus exaggerated sensitivity remains debated. Some research suggests Sincalide may be overly sensitive in certain populations.

3. Pediatric Dosing

While Sincalide is used in children, optimal dosing strategies remain understudied. Current protocols extrapolate from adult data; dedicated pediatric trials could refine safety and efficacy in this population.

4. Comparison with Emerging Alternatives

Newer diagnostic modalities (e.g., advanced MRI, elastography) are emerging. Head-to-head trials comparing Sincalide-HIDA with these methods are limited, leaving gaps in evidence for relative utility.

Related Compounds and Peptide Context

Sincalide exemplifies a peptide therapeutic approved for diagnostic rather than therapeutic use. For context, explore related peptides:

Octreotide: An approved somatostatin analog used for symptom management, also FDA-approved
Exenatide: A GLP-1 receptor agonist approved for diabetes; demonstrates how peptides transition from research to routine clinical care
Secretin: Another hormone-mimicking peptide used in diagnostic testing, structurally and functionally related to Sincalide

Understanding Sincalide's success illuminates why some peptides achieve clinical approval while others remain under investigation.

What Makes Sincalide Evidence Grade A?

Sincalide earned its highest evidence grade through:

Consistency: Multiple trials confirm the same diagnostic utility
Replicability: Results hold across diverse patient populations and centers
Duration: Decades of real-world clinical use validate safety
Regulatory agreement: Approval in major markets reflects rigorous review
Mechanistic clarity: The action of Sincalide as a CCK-receptor agonist is well-understood and directly observed

The Bottom Line

Sincalide research represents a mature evidence base. The compound is safe, effective, and approved for diagnostic use in North America. Clinical trials continue, but they refine application rather than establish fundamental efficacy. For clinicians, the evidence supports routine use in evaluating suspected biliary dyskinesia. For researchers, Sincalide serves as a model of how peptide therapeutics can transition from experimental to standard clinical tools.

Sincalide Research Evidence: What Clinical Trials & Studies Show